- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Father of Evidence-Based Medicine, Dr Sackett, Passes Away
In his own words, "The practice of evidence-based medicine means integrating individual clinical expertise with the best available external clinical evidence from systematic research."
The key thing that differentiates modern medicine from the healing arts of the past is its embrace of science. And few people did more to advance that cause than David Sackett.
Sackett, who died on Wednesday at the age of 80, was widely known as the father of the "evidence-based medicine" movement—arguably one of the most important recent advances in medical practice.
Many people might wonder, "Wasn't medicine always evidence-based?" Not necessarily. Until researchers like Sackett started to push the profession in a more scientific direction in the 1990s, a surprising amount of medical practice was simply rooted in expert opinion and whatever doctors learned in medical school — not the best or most up-to-date knowledge. But then came "evidence-based medicine.
Complete report on Vox: http://bit.ly/1GcXv3A
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
